Factors Affecting the Circulating Levels of Oxyntomodulin in Health and After Acute Pancreatitis.

Autor:	Bharmal SH; From the School of Medicine, University of Auckland, Auckland, New Zealand., Ko J; From the School of Medicine, University of Auckland, Auckland, New Zealand., Kimita W; From the School of Medicine, University of Auckland, Auckland, New Zealand., Cho J; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea., Petrov MS; From the School of Medicine, University of Auckland, Auckland, New Zealand.
Jazyk:	angličtina
Zdroj:	Pancreas [Pancreas] 2022 Aug 01; Vol. 51 (7), pp. 774-783.
DOI:	10.1097/MPA.0000000000002114
Abstrakt:	Objectives: To investigate the factors associated with the circulating levels of oxyntomodulin in healthy individuals and individuals after an episode of acute pancreatitis (AP). Methods: Blood samples were collected from all participants after an overnight fast and analyzed for 28 biomarkers. Participants also underwent comprehensive body composition analysis on a 3-T magnetic resonance imaging scanner. Regression analyses were done to investigate the associations between oxyntomodulin and the studied factors. Results: The study included 105 individuals who had a primary diagnosis of AP and 58 healthy individuals. Peptide YY (B coefficient, 0.094; 95% confidence interval [95% CI], 0.164-0.123), pancreatic polypeptide (0.048; 95% CI, 0.030-0.066), and leptin (0.394; 95% CI, 0.128-0.661) had significant associations with oxyntomodulin in healthy individuals. Peptide YY was the most prominent factor associated with oxyntomodulin, explaining 60% of its variance in health. Cholecystokinin (0.014; 95% CI, 0.010-0.018), amylin (-0.107; 95% CI, -0.192 to -0.021), and glycated hemoglobin (-0.761; 95% CI, -1.249 to -0.273) had significant associations with oxyntomodulin in individuals after AP. Cholecystokinin was the most prominent factor associated with oxyntomodulin, explaining 44% of its variance after AP. Conclusions: Factors affecting the circulating levels of oxyntomodulin are different in health and after AP. These insights will enable the determination of populations that benefit from oxyntomodulin therapeutics in the future. Competing Interests: The authors declare no conflict of interest. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu